PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15103451-0	2004	Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.	Acetylcholine	24-37	neuropeptide Y	Homo sapiens	0-14	
15103451-3	2004	We investigated whether the sympathetic cotransmitters neuropeptide Y (NPY), norepinephrine (NE), and ATP are capable of modulating acetylcholine release in human heart atrium.	Acetylcholine	132-145	neuropeptide Y	Homo sapiens	55-69	
15103451-3	2004	We investigated whether the sympathetic cotransmitters neuropeptide Y (NPY), norepinephrine (NE), and ATP are capable of modulating acetylcholine release in human heart atrium.	Acetylcholine	132-145	neuropeptide Y	Homo sapiens	71-74	
15103451-7	2004	NPY (0.05-1.0 micromol/l) concentration dependently inhibited acetylcholine release.	Acetylcholine	62-75	neuropeptide Y	Homo sapiens	0-3	
8335860-10	1993	CONCLUSIONS: These observations suggest that NPY inhibits the output of acetylcholine from nerve endings and that endogenous neutral endopeptidase modulates the effect of NPY in the human airway by inactivating this peptide.	Acetylcholine	72-85	neuropeptide Y	Homo sapiens	45-48	
10573779-9	1999	Inhibition of ACh release can be obtained by stimulation of various receptors on cholinergic nerves, including alpha 2-adrenoceptors, receptors for neuropeptide Y and galanin, or by antagonism of neuronal 5-HT4 receptors.	Acetylcholine	14-17	neuropeptide Y	Homo sapiens	148-174	
2346958-12	1990	Local release of neuropeptide Y during cardiac ischaemia may be involved in the regulation of coronary vascular tone as well as in the release of noradrenaline and acetylcholine.	Acetylcholine	164-177	neuropeptide Y	Homo sapiens	17-31	
25344273-8	2015	In this symposium report, I review the evidence that NPY can inhibit acetylcholine release during vagus nerve stimulation and limit the subsequent bradycardia.	Acetylcholine	69-82	neuropeptide Y	Homo sapiens	53-56	
2455195-4	1987	Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels.	Acetylcholine	202-215	neuropeptide Y	Homo sapiens	53-56	
2455195-4	1987	Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels.	Acetylcholine	217-220	neuropeptide Y	Homo sapiens	37-51	
2455195-4	1987	Examples include the interactions of neuropeptide Y (NPY) with noradrenaline (NA) and adenosine 5"-triphosphate (ATP) released from some sympathetic nerves; vasoactive intestinal polypeptide (VIP) with acetylcholine (ACh) released from some parasympathetic nerves; and NPY and 5-hydroxytryptamine (5-HT) released from intracardiac neurones supplying coronary vessels.	Acetylcholine	217-220	neuropeptide Y	Homo sapiens	53-56	
28775269-4	2017	We show that NPY transmission and HIPP cell activity contribute to inhibitory effects of acetylcholine in the dentate gyrus and that M1 muscarinic receptors mediate the cholinergic activation of HIPP cells as well as their control of background context salience.	Acetylcholine	89-102	neuropeptide Y	Homo sapiens	13-16	
24005254-6	2013	Recent data demonstrates a direct action of the sympathetic cotransmitters neuropeptide Y (NPY) and galanin on the ability of the vagus to release acetylcholine and control heart rate.	Acetylcholine	147-160	neuropeptide Y	Homo sapiens	91-94